FierceBiotech

Theriva puts GvHD drug on back burner to focus on oncolytic adenovirus

Theriva Biologics is putting more of its eggs in the VCN-01 basket as it unveils a change-up in its R&D focus. Last fall, SYN-004, also known as ribaxamase, finished a second cohort part of a phase 1b ...
The Manila Times

ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference

ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference ...
Fierce Biotech

Candel glows brighter with $100M RTW royalty deal to fund prostate cancer drug's launch

As Candel Therapeutics gears up for a planned U.S. approval push for its prostate cancer drug later this year, RTW ...

ViroMissile Expands Phase I IDOV-ImmuneTM Trial to U.S. Sites Following IND Clearance

SAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV (TM) (Intravenously Deliverable Oncolytic Virus) platform, today announced the ...
FOX40 News

Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma

Paris, France, June 4 th, 2025. Oncovita, a biotechnology company developing innovative virus-based immunotherapies for cancer treatment, today announced that the U.S. Food and Drug Administration ...